We’re Speaking Out on Health Issues

NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.

Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.

Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.

NCHR Testimony at FDA on Avastin

June 28, 2011. National Research Center of Women & Families President Diana Zuckerman testifies at the FDA meeting on Avastin.

NCHR Testimony at a House of Representatives Briefing on Medical Devices

May 17, 2011. Lives could be saved and patients would spend less time in the hospital if the FDA implemented the law as required by using the PMA process for all devices that are potentially dangerous in predictable ways.

Testimony of of Dr. Diana Zuckerman at Senate Special Committee on Aging Hearing on Medical Devices

April 13, 2011: Dr Diana Zuckerman of NCHR testified at a Senate Special Committee on Aging Hearing on medical devices, explaining FDA low standards for approval. She said lives could be saved and patients would spend less time in the hospital if FDA implemented the law as required. Billions of Medicare dollars could be saved.

NCHR Comment to the FDA on Strengthening the Center for Devices and Radiological Health’s 510(k) Review Process

March 19, 2010. Many people in the medical device industry claim that stricter standards for clearing or approving medical devices will stifle innovation.

NCHR Testimony Regarding Senate Bill 1449 Bisphenol A-Free Children and Babies Act

February 1, 2011. Our Center strongly supports Senate Bill 1449, which will help to ensure that Virginia’s children are better protected from the adverse health effects of BPA.